M. Merino

Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.

K. Norga, K. Wilner, Martha Donoghue, 2021, European journal of cancer.

FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma

R. Pazdur, G. Reaman, Y. Kasamon, 2022, Pediatric blood & cancer.

Dissociation of Pubertal Development Abnormality and Gonadal Dysfunction in Childhood Cancer Survivors.

R. Fritz, Mario Vega, M. Merino, 2020, Journal of adolescent and young adult oncology.

FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients

R. Pazdur, G. Reaman, A. Farrell, 2020, Pediatric blood & cancer.

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.

R. Pazdur, Y. Kasamon, M. Theoret, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.